Rigel Competitors
| RIGL Stock | USD 35.55 1.23 3.58% |
Rigel Pharmaceuticals vs Omeros Correlation
Good diversification
The correlation between Rigel Pharmaceuticals and OMER is -0.07 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Rigel Pharmaceuticals and OMER in the same portfolio, assuming nothing else is changed.
Moving against Rigel Stock
| 0.76 | DRTS | Alpha Tau Medical | PairCorr |
| 0.71 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.65 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.64 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.58 | CMB | Cambium Bio | PairCorr |
Rigel Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Rigel Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Rigel and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Rigel Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Rigel Stock performing well and Rigel Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Rigel Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOSS | 3.95 | (0.03) | (0.01) | (0.01) | 4.83 | 8.77 | 27.11 | |||
| KALV | 3.38 | 0.49 | 0.12 | 0.43 | 3.55 | 8.43 | 25.15 | |||
| PRTA | 2.33 | (0.31) | 0.00 | (0.12) | 0.00 | 5.10 | 14.00 | |||
| VTYX | 3.35 | 0.83 | 0.17 | (4.65) | 3.21 | 9.00 | 37.04 | |||
| FDMT | 3.82 | (0.08) | (0.01) | 0.01 | 6.26 | 7.04 | 27.09 | |||
| AKBA | 3.07 | (0.49) | 0.00 | (0.34) | 0.00 | 5.59 | 20.64 | |||
| CRVS | 6.58 | 2.79 | 0.56 | (0.40) | 3.10 | 9.63 | 174.42 | |||
| OLMA | 6.27 | 2.50 | 0.56 | (0.74) | 3.03 | 9.82 | 145.73 | |||
| BCYC | 2.69 | (0.37) | 0.00 | (0.23) | 0.00 | 6.06 | 14.20 | |||
| OMER | 5.49 | 1.31 | 0.24 | 8.76 | 4.29 | 12.62 | 87.69 |
Cross Equities Net Income Analysis
Compare Rigel Pharmaceuticals and related stocks such as Gossamer Bio, Kalvista Pharmaceuticals, and Prothena plc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.8 M) | (147 M) | (180.8 M) | (243.4 M) | (234 M) | (229.4 M) | (179.8 M) | (56.5 M) | (50.9 M) | (53.4 M) |
| KALV | (2.1 M) | (2.1 M) | (2.1 M) | (5.7 M) | (13.4 M) | (24.8 M) | (18.6 M) | (15.8 M) | (20.8 M) | (29.1 M) | (46.2 M) | (82.3 M) | (92.9 M) | (126.6 M) | (183.4 M) | (24.8 M) | (26.1 M) |
| PRTA | (12.5 M) | (29.7 M) | (41.4 M) | (41 M) | (7.2 M) | (80.6 M) | (160.1 M) | (153.2 M) | (155.6 M) | (77.7 M) | (111.1 M) | 67 M | (116.9 M) | (147 M) | (122.3 M) | (110.1 M) | (115.6 M) |
| VTYX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (28.2 M) | (83.7 M) | (108.4 M) | (193 M) | (135.1 M) | (121.6 M) | (127.7 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (68.3 M) | (101.1 M) | (100.8 M) | (160.9 M) | (144.8 M) | (137.5 M) |
| AKBA | (8.2 M) | (8.2 M) | (8.2 M) | (13.2 M) | (37 M) | (60.7 M) | (135.7 M) | (76.9 M) | (171.9 M) | (279.7 M) | (349.9 M) | (244.9 M) | (94.2 M) | (51.9 M) | (69.4 M) | (62.5 M) | (65.6 M) |
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (31.3 M) | (36.4 M) | (55.7 M) | (46.9 M) | (43.7 M) | (4.8 M) | (43.2 M) | (41.3 M) | (27 M) | (62.3 M) | (56.1 M) | (58.9 M) |
| OLMA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (4.3 M) | (22.1 M) | (71.1 M) | (102.6 M) | (96.7 M) | (129.5 M) | (116.5 M) | (110.7 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.3 M) | (21.8 M) | (30.6 M) | (51 M) | (66.8 M) | (112.7 M) | (180.7 M) | (169 M) | (152.1 M) | (144.5 M) |
| OMER | (7.4 M) | (28.5 M) | (38.4 M) | (39.8 M) | (73.7 M) | (75.1 M) | (66.7 M) | (53.5 M) | (126.8 M) | (84.5 M) | (138.1 M) | (111.4 M) | 47.4 M | (117.8 M) | (156.8 M) | (141.1 M) | (134.1 M) |
Rigel Pharmaceuticals and related stocks such as Gossamer Bio, Kalvista Pharmaceuticals, and Prothena plc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Rigel Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Rigel Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Rigel Pharmaceuticals Competitive Analysis
The better you understand Rigel Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Rigel Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Rigel Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Rigel Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Rigel Pharmaceuticals Competition
Rigel Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Rigel Pharmaceuticals in relation to its competition. Rigel Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Rigel Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Rigel Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Rigel Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Rigel Pharmaceuticals position
In addition to having Rigel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Rigel Pharmaceuticals Correlation with its peers. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. Anticipated expansion of Rigel directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Rigel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.086 | Earnings Share 6.19 | Revenue Per Share | Quarterly Revenue Growth 0.256 | Return On Assets |
Investors evaluate Rigel Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rigel Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Rigel Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Rigel Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rigel Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rigel Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.